文献速递骨软组织肉瘤与黑色素瘤

贝伐珠单抗联合卡铂紫杉醇一线治疗晚期黏膜黑色素瘤的随机II期研究

Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma.
PubMed 文献 · J Clin Oncol · 2021-01-14

该随机开放标签II期研究纳入114例既往未治疗的晚期黏膜黑色素瘤患者,按2:1随机接受卡铂+紫杉醇联合或不联合贝伐珠单抗治疗。

要点

  • 贝伐珠单抗联合卡铂紫杉醇显著延长晚期黏膜黑色素瘤患者的PFS和OS。

核心结论

  • 在晚期黏膜黑色素瘤患者中,卡铂紫杉醇联合贝伐珠单抗较单用化疗显著改善PFS和OS。

研究设计与样本

  • 随机、开放标签、II期研究,纳入114例既往未治疗的晚期黏膜黑色素瘤患者,按2:1随机分配。
  • 联合组(CPB)接受卡铂(AUC 5)+紫杉醇(175 mg/m2)每4周一次+贝伐珠单抗(5 mg/kg)每2周一次;对照组(CP)仅接受卡铂+紫杉醇。

主要发现

  • 未观察到新的安全性信号。

关键数值与推荐

  • 主要终点为PFS,次要终点包括OS、客观缓解率和不良事件。
  • 卡铂剂量按AUC 5计算,紫杉醇175 mg/m2,贝伐珠单抗5 mg/kg。

临床怎么用

  • 对于既往未治疗的晚期黏膜黑色素瘤患者,可考虑在卡铂+紫杉醇基础上联合贝伐珠单抗以改善PFS和OS。
  • 该方案的安全性未发现新信号,但需进一步III期研究确认获益。

局限性

  • 为II期研究,样本量有限,结论需III期研究验证。
  • 开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Mucosal melanoma (MM) is a highly vascularized tumor with an extremely poor prognosis. In this randomized, open-label, phase II study, we characterized the efficacy and safety of bevacizumab in combination with carboplatin plus paclitaxel (CPB) in patients with previously untreated advanced MM. PATIENTS AND METHODS: Patients were randomly assigned in a 2:1 ratio to receive carboplatin (area under the curve, 5) plus paclitaxel (175 mg/m2) once every 4 weeks in combination with (CPB arm, 5 mg/kg) or without (CP arm) bevacizumab once every 2 weeks. Progression-free survival (PFS) was the primary end point. Secondary end points included overall survival (OS), objective response rate, and adverse events. RESULTS: We recruited 114 patients to our study. The median PFS was significantly longer in the CPB arm (4.8 months; 95% CI, 3.6 to 6.0 months) than in the CP arm (3.0 months; 95% CI, 1.7 to 4.3 months) (hazard ratio, 0.461; 95% CI, 0.306 to 0.695; P < .001). Objective response rates were 19.7% and 13.2%, respectively (P = .384). The median OS was also significantly longer in the CPB arm than in the CP arm (13.6 v 9.0 months; hazard ratio, 0.611; 95% CI, 0.407 to 0.917; P = .017). No new safety signals were observed. CONCLUSION: PFS and OS were significantly better in patients with metastatic MM who received bevacizumab in addition to CPB than in those who received CPB alone. A phase III study should be performed to confirm these benefits (ClinicalTrials.gov identifier: NCT02023710).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yan X, Sheng X, Chi Z, et al. Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. J Clin Oncol. 2021. PMID: 33444116. doi:10.1200/JCO.20.00902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。